Abstract:Abstract BackgroundNAFLD is a common metabolic disorders disease which influenced 20~30% people. NAFLD can progress to cirrhosis, liver fibrosis and even liver cancer. Liver puncture is the gold standard. However, due to its trauma and possible complications, its clinical use is currently limited. Therefore, it is of great clinical significance and value to find a noninvasive biochemical index that can diagnose NAFLD early.ObjectiveOur aim was to identify the potential biomarkers in NAFLD people in early stage via untargeted metabolomics study.MethodsIn our research, From January to October 2019, 224 patients aged 18-55 were selected from the outpatient department and ward of gastroenterology department of Putuo Hospital in Shanghai.According to the NAFLD diagnostic criteria of the guidelines for diagnosis and treatment of nonalcoholic fatty liver disease (2018) formulated by the National workship on Fatty liver and alcoholic liver disease and Chinese Society on Hepatology, they were divided into the healthy control group and the experimental group.Besides,on the same day, the height, weight, waist, BMI, blood pressure and heart rate of patients were measured, and fasting blood was taken to obtain blood glucose,ALT, AST, TB, DB, TP, ALB, Che, ALP, γ - GT, TG, TC, HDL-C, LDL-C and other serum data.Serum samples were analyzed using LC/MS and data was processed by SIEVE software and simca-P to validate the potential biomarkers. The altered metabolites were identified by variable importance in projection value (VIP > 1) and ANOVA ( p< 0.01). The pathway analysis was performed by using MetaboAnalyst 4.0. In addition, our project has passed the review of ethics committee of Putuo Hospital Affiliated to Shanghai University of traditional Chinese medicine, and its ethics approval number is ptec-a-2018-49-1.ResultsThe serum biochemical indicators of early NAFLD patients showed no significant difference with NC ( p>0.05 ). While there was significant difference of blood lipids indicators between NAFLD and NC ( p<0.001 ). Finally, 55 metabolites were identified and the AUC of ROC curve results showed that new identified biomarkers owned high predictability and reliability. ConclusionIt is found that 15 metabolites in serum were of great diagnostic value in early NAFLD patients. AUC of these biomarkers (>0.9) were much higher than clinical indicators (0.770). This may be worth further research in the clinic.

Progress in Serum Markers for Non-Alcoholic Fatty Liver Disease

[Research Advances in Diagnosis of Non-Alcoholic Fatty Liver Disease].

[Advances in epidemiology and serum markers for the noninvasive diagnosis of nonalcoholic fatty liver disease].

Advances in Noninvasive Methods for Diagnosing Nonalcoholic Fatty Liver Disease

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.

Non-Invasive Serum Markers of Non-Alcoholic Fatty Liver Disease Fibrosis: Potential Tools for Detecting Patients with Cardiovascular Disease

Recent Progress of Proteomics in Nonalcoholic Fatty Liver Disease*

Serological noninvasive diagnosis in nonalcoholic steatohepatitis with fibrosis

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future

[New Advances in Diagnosis of Nonalcoholic Fatty Liver Disease].

Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease: Current Evidence and Practice.

LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Progress in Non-invasive Diagnosis and Assessment of Non-alcoholic Fatty Liver Disease

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

Potential New Biomarkers Discovery of Early Nonalcoholic Fatty Liver Disease in Human by Liquid Chromatography–Mass Spectrometry

Nonalcoholic fatty liver disease: an update on the diagnosis.

Blood-based Novel Biomarkers for Nonalcoholic Steatohepatitis